Study on Gavo-cel (TC-210) for Treating Advanced Cancers with Mesothelin Expression
Sponsor: TCR2 Therapeutics
ClinicalTrials ID:NCT03907852
This clinical trial is testing a new cell therapy called gavo-cel (TC-210) to see if it can help treat advanced cancers that express a protein called mesothelin. The study aims to find the best dose and evaluate how effective the treatment is, both alone and with other cancer-fighting drugs.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Gavo-cel (TC-210) is a new type of cell therapy that uses a patient's own genetically modified T cells to target and attack cancer cells that express a protein called mesothelin. This study is in two phases: Phase 1 will determine the best dose for treatment, and Phase 2 will assess how well the treatment works in controlling cancer. The main goals are to see how many patients respond to the treatment and how well the disease is controlled.
Eligibility Criteria
Inclusion Criteria
- Must be 18 years or older.
- Have a confirmed diagnosis of one of the following cancers: Malignant Pleural/Peritoneal Mesothelioma, Serous Ovarian Adenocarcinoma, Cholangiocarcinoma, or Non-Small Cell Lung Cancer.
- The cancer must show a certain level of mesothelin protein, as confirmed by lab tests.
- Must have tried at least one standard treatment for cancer that has spread or cannot be removed by surgery, except for some cases of Cholangiocarcinoma.
- Must not have had more than five previous treatments.
- Must be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
- Heart function must be sufficient, with a pumping ability above 45%.
- Must be able to undergo a procedure to collect cells from the blood.
- Must have adequate organ function as shown by specific lab tests.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of California, San Francisco | 94143 | San Francisco | California |
| University of Miami Sylvester Cancer Center | 33136 | Miami | Florida |
| University of Chicago Medical Center | 60637 | Chicago | Illinois |
| National Cancer Institute | 20814 | Bethesda | Maryland |
| Columbia University Medical Center | 10032 | New York | New York |
| Memorial Sloan Kettering Cancer Center | 10065 | New York | New York |
| Duke University | 27705 | Durham | North Carolina |
| University of Pennsylvania | 19104 | Philadelphia | Pennsylvania |
| SCRI Oncology Partners | 37203 | Nashville | Tennessee |
| University of Texas MD Anderson Cancer Center | 77030 | Houston | Texas |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.